The factors responsible for the production of autoantibodies against self-components are not well understood. We have identified monospecific human autoantibodies to poly(ADP-ribose) polymerase (ADPRP) in the sera of rheumatic patients. Since this nuclear enzyme has been extensively characterized, and its entire structure is known, we could investigate in detail the epitope specificity of the human autoantibodies, and their effects on the biological functions of the enzyme. All sera with autoantibodies to ADPRP recognized the NAD-binding domain of the enzyme, as demonstrated by either immunoblotting or immunoprecipitation of partially proteolyzed ADPRP. The autoantibodies also inhibited the catalytic activity of the purified enzyme, as measured by the transfer of ADP-ribose from I32PJNAD to either histones or to ADPRP itself. Because comparative structural analyses have shown that the active sites of enzymes are often conserved during evolution, we tested the ability of the autoantibodies to react with ADPRP from lower eukaryotes. The human autoantibodies reacted with ADPRP in cellular extracts from mammalian, avian, amphibian, arthropod, and protozoan cells, and also inhibited the catalytic activity of the various enzymes. Collectively, these experiments indicate that the human autoantibodies to ADPRP recognize a distinct group of evolutionarily conserved antigenic determinants that are closely related to the catalytic site of the enzyme. The results are consistent with the hypothesis that the epitope selectivity of human autoantibodies to ADPRP is influenced by cross-reactive antigens in the external environment.
Introduction
Nuclear proteins are common targets of autoimmune responses in patients with systemic rheumatic diseases (1, 2) . It is still not clear how abnormal immune regulation leads to the repeated production of autoantibodies against such a highly selected group of self-components. To approach this problem, it is important to localize the exact autoantigenic epitopes on nuclear proteins. However, the performance of such investigations requires knowledge of the structure and biological function of the antigen under analysis.
Recently, we identified high titer and monospecific autoantibodies against poly(ADP-ribose) polymerase (ADPRP)l in several rheumatic patients (3) . ADPRP [E.C. 2.4.2.30 ] is a eukaryotic nuclear enzyme that has been characterized extensively (4, 5) . Recently, cDNA clones of the human enzyme have been isolated, and its sequence has been completely determined (6) (7) (8) . ADPRP consists of a single 1 16-kD polypeptide that catalyzes the DNA-dependent transfer of ADP-ribose units from NAD to nuclear proteins, to form elongated and branched poly(ADP-ribose) chains (4) . This posttranslational modification of nuclear proteins occurs particularly at regions of DNA strand break formation (4, 9) , and may be important in the modulation of chromatin structure that accompanies DNA repair (10) and cell differentiation (I 1) in eukaryotes.
In this report, we have investigated the specificities of the human autoantibodies against ADPRP, and their effects on the biological function of the enzyme. Our results demonstrate that the autoantibodies all recognize an epitope that is associated with the catalytic site of ADPRP, and that is expressed by the enzyme in both higher and lower eukaryotes. The restricted specificity and cross-reactivity ofthe autoantibodies to ADPRP are consistent with the hypothesis that antigens in the external environment influence the epitope specificity of human autoantibodies to nuclear proteins.
Methods
Autoantibodies. The sera containing autoantibodies against ADPRP have been described previously (3) . The IgG fractions were purified by ammonium sulfate precipitation, followed by DEAE column chromatography (12) . In some experiments, antibodies were purified by affinity chromatography, using an ADPRP-conjugated Sepharose column, as described earlier (3 (Fig. 2 B) , corre- Papain al-Chy otry sion sponding to histone Hi. These poly(ADP-ribosyl)ation reactions were totally inhibited by the ADPRP inhibitor, 3-aminobenzamide, but were not affected by normal IgG. The anti-ADPRP autoantibodies from patient ED, that react with both the NAD-binding and DNA-binding domains, blocked the poly(ADP-ribosyl)ation reactions. However, the autoantibodies from patient CM (lane 2 in Fig. 1) , that recognize exclusively the 54-kD NAD-binding domain ofADPRP, also inhibited enzyme activity. These results indicate that autoantibody interaction with the NAD-binding domain is sufficient to block ADPRP catalytic activity. Inhibition ofADPRP interaction with DNA. The catalytic activity of ALPRP is strongly stimulated by DNA, especially by DNA with breaks or nicks (9) . To prove that the autoantibodies from patient CM did not impair the interaction of ADPRP with DNA, DNA-protein binding assays were performed. These experiments were possible because the tested sera with anti-ADPRP autoantibodies lacked detectable anti-DNA antibody activity (3). As shown in Table I , the formation of a protein-DNA complex was perturbed by preincubation of ADPRP with autoantibodies with specificity for both the DNA-binding and NAD-binding domains (ED IgG, Table I ). (Fig. 4 A) . In HeLa and Xenopus extracts, radioactive smears of 116 kD and higher were visualized; in Crithidia 80-100-kD bands were observed. The heterogenous molecular mass of the radiolabeled polypeptides probably reflects the variable length of the ADP-ribose chains, and perhaps the partial proteolysis of the enzyme. Indeed, ADPRP activity in Crithidia was only detectable if the cells were ex- tracted into buffer containing protease inhibitors, and were processed immediately.
Finally, to confirm that the cross-reactive human autoantibodies to ADPRP recognized determinants related to the catalytic site of the enzyme, the effects of IgG on enzymatic activity were tested. In both HeLa cells and Xenopus eggs, enzyme automodification was inhibited by 3-aminobenzamide and by human autoantibodies to ADPRP, but not by normal IgG. In Crithidia extracts, the poly(ADP-ribosyl)ated bands that were observed at -75 and 50 kD, were also specifically inhibited by 3-aminobenzamide and by human autoantibodies (Fig. 4  B) . Similar experiments demonstrated the ability of the autoantibodies to inhibit ADPRP activity in mammalian, avian, arthropod, and protozoan cells (results not shown).
Discussion
Among the thousands of different proteins that can be produced by human cells, less than 100 have thus far been shown to be recognized by autoantibodies in patients with rheumatic diseases. Structural and molecular analyses of several protein autoantigens have revealed certain recurrent properties, although no absolute associations (1). Many autoantigens are relatively abundant proteins, that often are organized into particulate, multifunctional complexes involved in DNA replication, transcription, or translation (21, 22) . The autoantigenic proteins frequently have either local areas of charge, or repeating sequences, that facilitate their interaction with DNA and RNA (23, 24) . Because of their essential roles in cellular metabolism, the basic structures of nuclear proteins tend to be conserved among species (2, 25) .
Recent experiments have revealed that ADPRP is also an abundant DNA-binding protein. However, ADPRP has the unique ability to catalyze the sequential transfer of ADP-ribose residues from NAD to the enzyme molecule itself (4). This automodification reaction modulates the interaction ofADPRP with DNA, and may also play a role in the regulation of NAD turnover (29 showed that all the autoantibodies reacted with the NADbinding domain, while only three of seven recognized both domains. Furthermore, autoantibodies that recognized exclusively the NAD-binding domain could block ADPRP catalytic activity.
Recently, cDNA clones for human ADPRP have been isolated, and the entire primary structure of the enzyme has been determined (6) (7) (8) 30 ). In addition, bacterial fusion proteins that express the major autoantigenic epitope in the NAD-binding domain have been generated (30) . This autoantigenic fragment of ADPRP has a predicted secondary structure that is reminiscent of other NAD-utilizing dehydrogenases. A portion of the NAD-binding region is both hydrophilic and flexible, and therefore should be readily accessible to autoantibodies (C. Penning, H. Yamanaka, D. A. Carson, et al., unpublished observations). Taken together with the results of the present experiments, these considerations suggest that the principal autoantigenic epitope on ADPRP is closely related to the NAD-binding catalytic site.
The structural characteristics of the nucleotide binding domains of enzymes generally have been conserved during molecular evolution, since they are under selective pressure to maintain a unique function (31, 32) . Hence, the recognition of the NAD-binding site of ADPRP by the human autoantibodies is entirely consistent with their ability to immunoprecipitate the enzyme from evolutionarily divergent species, and to inhibit the poly(ADP-ribosyl)ation reaction. The results emphasize the close relationship between the conserved catalytic site of this nuclear enzyme and its major autoantigenic epitope.
In summary, these experiments have shown (a) that the NAD-binding region of ADPRP is the only part of the molecule that is recognized by every sera containing autoantibodies against the enzyme, (b) that the autoantibodies recognize ADPRP in diverse eukaryotes, and (c) that the autoantibodies inhibit ADPRP catalytic activity. In part, such precise epitope specificity could be attributed to the intrinsic antigenicity of the enzyme's active site. However, it is also reasonable to propose that the selective production ofautoantibodies against the conserved catalytic site ofADPRP is influenced by exposure of the immune system to cross-reactive enzymes in the external environment. According to this hypothesis, foreign determinants on ADPRP from different species might act as carriers that facilitate the repeated stimulation of B lymphocytes producing cross-reactive antibodies reactive with the catalytic site of the human enzyme. In this regard, it is notable that human autoantibodies against alanyl-tRNA synthetase (33) , RNA polymerase I (34) , and topoisomerase I (35) , have also been observed to inhibit the activities ofthese enzymes. Gilbert (32) originally suggested that the nucleotide binding domains of enzymes are encoded by distinct exons that have been shuffled from one gene to another during evolution. However, a relationship between the autoantigenic epitopes of nuclear proteins and particular exon units has not been established. A detailed comparison of the structure and organization of the ADPRP gene in different species should reveal whether or not the major autoantigenic region corresponds to one or more exons that are conserved in eukaryotic DNA.
